Loading…
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-88M | $-75M | $-67M | -24.5% | - | - |
| 2024 | $0M | $-70M | $-62M | $-53M | 37.7% | - | - |
| 2023 | $0M | $-50M | $-47M | $-45M | 41.1% | - | - |
| 2022 | $0M | $-41M | $-40M | $-38M | 57.5% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 41.37 | 50.33 | 70.56 | 88.98 |
| Operating Income | -41.37 | -50.33 | -70.56 | -88.98 |
| EBITDA | -41.25 | -49.75 | -69.89 | -88.33 |
| EBIT | -41.37 | -50.33 | -70.56 | -88.98 |
| Pretax Income | -40.24 | -47.26 | -61.69 | -75.27 |
| Net Income | -40.24 | -47.26 | -61.69 | -75.27 |
| Net Income Common Stockholders | -40.24 | -47.26 | -61.69 | -75.27 |
| Total Expenses | 41.37 | 50.33 | 70.56 | 88.98 |
| Interest Income | 1.13 | 2.77 | 8.17 | 13.29 |
| Research And Development | 34.60 | 40.63 | 57.29 | 60.26 |
| Selling General And Administration | 6.77 | 9.71 | 13.27 | 28.72 |
| Normalized EBITDA | -41.25 | -49.75 | -69.89 | -88.33 |
| Normalized Income | -40.24 | -47.26 | -61.69 | -75.27 |
| Basic EPS | -2.32 | -1.70 | -1.45 | 0 |
| Diluted EPS | -2.32 | -1.70 | -1.45 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -40.24 | -47.26 | -61.69 | -75.27 |
| Reconciled Depreciation | 0.12 | 0.58 | 0.67 | 0.65 |
| Net Interest Income | 1.13 | 2.77 | 8.17 | 13.29 |
| Net Income From Continuing And Discontinued Operation | -40.24 | -47.26 | -61.69 | -75.27 |
| Total Operating Income As Reported | -41.37 | -50.33 | -70.56 | -88.98 |
| Diluted Average Shares | 17.33 | 27.80 | 42.44 | 0 |
| Basic Average Shares | 17.33 | 27.80 | 42.44 | 0 |
| Diluted NI Availto Com Stockholders | -40.24 | -47.26 | -61.69 | -75.27 |
| Net Income Including Noncontrolling Interests | -40.24 | -47.26 | -61.69 | -75.27 |
| Net Income Continuous Operations | -40.24 | -47.26 | -61.69 | -75.27 |
| Other Income Expense | 0 | 0.30 | 0.70 | 0.42 |
| Other Non Operating Income Expenses | 0 | 0.30 | 0.70 | 0.42 |
| Net Non Operating Interest Income Expense | 1.13 | 2.77 | 8.17 | 13.29 |
| Interest Income Non Operating | 1.13 | 2.77 | 8.17 | 13.29 |
| General And Administrative Expense | 6.77 | 9.71 | 13.27 | 28.72 |
| Other Gand A | 2.28 | 3.78 | 5.43 | 9.82 |
| Salaries And Wages | 4.48 | 5.92 | 7.84 | 18.90 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Sionna Therapeutics, Inc.this co. | SION | $1.7B | - | 5.46 | -24.5% | -16.50 |
| Harmony Biosciences Holdings, Inc. | HRMY | $1.8B | 11.23 | 2.05 | 18.2% | 4.68 |
| Palvella Therapeutics, Inc. | PVLA | $1.8B | - | 54.18 | -149.1% | - |
| Recursion Pharmaceuticals, Inc. | RXRX | $1.7B | - | 1.54 | -57.0% | -1.91 |
| Amylyx Pharmaceuticals, Inc. | AMLX |
| $1.7B |
| - |
| 5.62 |
| -47.4% |
| -9.25 |
| Nurix Therapeutics, Inc. | NRIX | $1.7B | - | 3.57 | -49.1% | -4.02 |
| Agios Pharmaceuticals, Inc. | AGIO | $1.7B | - | 1.37 | -34.6% | -1.37 |
| Astrana Health, Inc. | ASTH | $1.6B | 83.54 | 2.41 | 2.9% | 18.68 |
| Healthcare Services Group, Inc. | HCSG | $1.6B | 26.18 | 3.03 | 11.6% | 16.59 |
| Peer Median | - | 26.18 | 2.72 | -41.0% | -1.37 | |